Cytokinetics Awaits Amgen's Phase III Plan After Phase II Heart Drug Success
This article was originally published in Scrip
Next steps in the development of heart failure drug omecamtiv mecarbil are unclear following the successful conclusion of a Phase II clinical trial while Cytokinetics Inc. waits to determine with partner Amgen Inc. whether the mid-stage data are sufficient to justify investment in a Phase III program.
You may also be interested in...
Analysts considered the Phase III GALACTIC-HF study of omecamtiv mecarbil a failure but some anticipated that detailed data to be presented next month could at least partially redeem the drug.
Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.
Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.